Vmbook Online ordering

Nephrogenex Inc

NephroGenex, Inc. was a biopharmaceutical company focused on the development of therapeutics to treat chronic kidney disease (CKD) and its complications. The company's lead product was Pyridorin, a drug candidate that was being developed for the prevention of kidney function decline in patients with diabetic nephropathy.

NephroGenex was a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol "NPHX". However, it's important to note that the company is no longer in operation. NephroGenex filed for Chapter 7 bankruptcy in December 2016, and its assets were liquidated.

At the time of its bankruptcy, NephroGenex reportedly had approximately $7.5 million in assets and $22.6 million in liabilities. The company's failure was largely attributed to the disappointing results of a Phase 3 clinical trial of Pyridorin, which failed to meet its primary endpoint of significantly slowing the decline of kidney function in patients with diabetic nephropathy.

Since the company is no longer in operation, there is no current financial or operational information available for NephroGenex, and its stock is no longer trading on NASDAQ.